Wells Fargo Downgrades Amgen to Equal-Weight, Raises Price Target to $335
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has downgraded Amgen (NASDAQ:AMGN) from Overweight to Equal-Weight while raising the price target from $320 to $335.
August 07, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo has downgraded Amgen from Overweight to Equal-Weight, but raised the price target from $320 to $335.
The downgrade from Overweight to Equal-Weight suggests a neutral stance on Amgen's stock, which could lead to a mixed market reaction. However, the raised price target to $335 indicates some positive outlook on the stock's potential. Overall, the impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100